journal
MENU ▼
Read by QxMD icon Read
search

Melanoma Research

journal
https://www.readbyqxmd.com/read/27824739/effect-of-the-lymphocyte-to-monocyte-ratio-on-the-clinical-outcome-of-chemotherapy-administration-in-advanced-melanoma-patients
#1
Alexey A Leontovich, Roxana S Dronca, Wendy K Nevala, Michael A Thompson, Lisa A Kottschade, Leonid V Ivanov, Svetomir N Markovic
Skin cancer affects more individuals in the USA than any other malignancy and malignant melanoma is particularly deadly because of its metastatic potential. Melanoma has been recognized as one of the most immunogenic malignancies; therefore, understanding the mechanisms of tumor-immune interaction is key for developing more efficient treatments. As the tumor microenvironment shows an immunosuppressive action, immunotherapeutic agents promoting endogenous immune response to cancer have been tested (interleukin-2, anticytotoxic-T-lymphocyte-associated antigen 4, and antiprogrammed cell death protein 1 monoclonal antibodies) as well as combinations of cytotoxic chemotherapy agents and inhibitors of angiogenesis (taxol/carboplatin/avastin)...
November 7, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27792059/vitamin-d-receptor-immunohistochemistry-variability-in-sun-exposed-and-non-sun-exposed-melanomas
#2
Giovanni Paolino, Chiara Panetta, Carlo Cota, Dario Didona, Elisa Moliterni, Cinzia Di Mattia, Gaetano De Vita, Ugo Bottoni, Pietro Donati, Stefano Calvieri
Ultraviolet rays are one of the leading factors in the development of melanoma (MM); however, ultraviolet rays seem not to play a role in non-sun-exposed MM, where systemic immunosuppression, anatomical, and physiological features may contribute toward the development of the malignancy. Our aim was to evaluate vitamin D receptor (VDR) expression in shield-site melanoma (ST-MM) and non-shield-site melanoma (NST-MM) to find features that could explain the different biological behavior of MM according to the area of onset...
October 27, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27792058/clinical-features-and-response-to-systemic-therapy-in-a-historical-cohort-of-advanced-or-unresectable-mucosal-melanoma
#3
Alexander N Shoushtari, Mark J Bluth, Debra A Goldman, Christiana Bitas, Robert A Lefkowitz, Michael A Postow, Rodrigo R Munhoz, Gauri Buchar, Robert H Hester, Jacqueline A Romero, Laura J Fitzpatrick, Martin R Weiser, Katherine S Panageas, Jedd D Wolchok, Paul B Chapman, Richard D Carvajal
There are very few data available regarding the pattern of first metastases in resected mucosal melanomas (MMs) as well as the response of advanced MM to cytotoxic therapy. A retrospective, single-institution cohort was assembled of all patients with advanced/unresectable MM between 1995 and 2012 who had received systemic therapy with available imaging (N=81). Responses to first-line and second-line systemic therapy were assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The relationship between response, overall survival, and clinical covariates was investigated using Cox proportional hazards regression...
October 27, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27776019/two-cases-of-clinical-myasthenia-gravis-associated-with-pembrolizumab-use-in-responding-melanoma-patients
#4
Bella H V Nguyen, James Kuo, Anadian Budiman, Hayden Christie, Sayed Ali
Immune checkpoint inhibitors have changed the landscape of the treatment of multiple solid malignancies, and have been used increasingly in the recent years. Although usually well tolerated, given the relative inexperience of using immune checkpoint inhibitors, we are still learning of new side effects from the treatment. We report on two cases of ocular myasthenia gravis that occurred after treatment with pembrolizumab, an antiprogrammed-death (anti-PD1) monoclonal antibody for advanced melanoma in responding patients...
October 21, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27776018/inhibitor-of-vasculogenic-mimicry-restores-sensitivity-of-resistant-melanoma-cells-to-dna-damaging-agents
#5
Amalia Vartanian, Maria Baryshnikova, Olga Burova, Dariya Afanasyeva, Vsevolod Misyurin, Alexander Belyаvsky, Zoya Shprakh
The increasing incidence of melanoma makes this cancer an important public health problem. Therapeutic resistance is still a major obstacle to the therapy of patients with metastatic melanomas. The aim of this study was to develop the melanoma cell line resistant to DNA-alkylating agents and to elucidate the mechanisms involved in acquired drug resistance. We established a unique melanoma subline Mel MeR resistant to DNA-alkylating drug aranoza by continuous stepwise selection of the Mel Me/WT cell line with increasing concentrations of this drug...
October 21, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27768639/high-cytotoxic-t-lymphocyte-associated-antigen-4-and-phospho-akt-expression-in-tumor-samples-predicts-poor-clinical-outcomes-in-ipilimumab-treated-melanoma-patients
#6
Nitin Chakravarti, Doina Ivan, Van A Trinh, Isabella C Glitza, Jonathan L Curry, Carlos Torres-Cabala, Michael T Tetzlaff, Roland L Bassett, Victor G Prieto, Wen-Jen Hwu
Ipilimumab, a fully human monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), is the first immune checkpoint inhibitor approved for the treatment of unresectable melanoma on the basis of its overall survival (OS) benefit. However, ipilimumab is associated with significant immune-related adverse events. We hypothesized that biomarker exploration of pretreatment tumor samples and correlation with clinical outcome would enable patient selection with an increased benefit/risk ratio for ipilimumab therapy...
October 20, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27764061/inflammatory-regulation-of-stem-like-cells-in-melanoma
#7
Ming-Sheng Lim, Jiang Huai Wang, Derek G Power, H Paul Redmond
The link between inflammation, immunity and cancer is well established. In the last decade, there has been considerable excitement over cancer stem cells, believed to be a subset of tumour cells responsible for their initiation, propagation and resistance to conventional chemoradiotherapy. In this review, we discuss the characterization of cancer stem cells and describe their modulation by inflammation with a focus on melanoma.
October 19, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27764060/adjuvant-external-beam-radiotherapy-after-therapeutic-groin-lymphadenectomy-for-patients-with-melanoma-a-dosimetric-comparison-of-three-dimensional-conformal-and-intensity-modulated-radiotherapy-techniques
#8
Gerard Adams, Matthew Foote, Simon Brown, Bryan Burmeister
Radiotherapy after lymph node dissection is recommended in high-risk melanoma cases. The aim of this study is to assess whether intensity-modulated radiotherapy (IMRT) offers advantages over three-dimensional conformal radiotherapy (3DCRT) in the groin nodal basin. Fifteen consecutively treated patients (5 3DCRT and 10 IMRT) were selected. Optimized theoretical plans using the other modality were created - enabling direct comparisons of 3DCRT and IMRT. Target volume and organs at risk constraints were assessed as achieved or as having minor (≤5%) or major (>5%) deviations...
October 19, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27759578/tumor-free-osteosclerotic-lesions-in-patients-treated-for-metastatic-melanoma-using-braf-inhibitors
#9
Lea Bottlaender, Marie Perier-Muzet, Véronique Lapras, Luc Thomas, Stephane Dalle
BRAF inhibitors (vemurafenib and dabrafenib) are nowadays commonly prescribed in BRAF-mutant metastatic melanoma and allow improvement of the overall survival and progression-free survival. They are, however, accompanied by many adverse effects which mainly affect the skin. We observed on computed tomographic scans in three different patients after 3 months of treatment, the onset of osteosclerotic lesions. In parallel, the computed tomographic scans showed a significant reduction in all of the previously identified metastases in all patients...
October 18, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27759577/a-case-report-of-bullous-pemphigoid-associated-with-a-melanoma-and-review-of-the-literature
#10
Kyle T Amber, Christine M Panganiban, Dorota Korta, Sebastien de Feraudy, Kristen M Kelly, Sergei A Grando
The association of bullous pemphigoid with melanoma remains controversial and poorly understood. Recent studies report the presence of the bullous pemphigoid antigen, BP180, in melanoma cells, yet not normal melanocytes, suggesting an underlying mechanism for cases of melanoma-associated bullous pemphigoid. We report on an 88-year-old woman who showed a temporal relationship between the development of bullous pemphigoid and melanoma. The patient did not receive programmed death ligand 1 inhibitor therapy and improved rapidly following complete excision of her melanoma, with clobetasol, doxycycline, and niacinamide...
October 18, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27753732/prospective-evaluation-of-prognostic-indicators-for-early-recurrence-of-cutaneous-melanoma
#11
Julia A H Matheson, Luc Te Marvelde, Sonia Mailer, David Speakman, John Spillane, Michael A Henderson, David E Gyorki
The majority of melanomas are thin lesions with an excellent prognosis; however, significant tumor heterogeneity exists, and a small percentage of patients with early-stage disease may progress to metastatic recurrence. This study aimed to assess whether prognostic factors previously shown to be significant in predicting stage I and stage II melanoma recurrence were consistent in a large prospectively collected patient cohort, and to identify novel prognostic factors associated with early recurrence to inform follow-up protocols...
October 6, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27623135/microsatellite-instability-in-melanoma-a-comprehensive-review
#12
Ondřej Kubeček, Jindřich Kopecký
Microsatellite instability (MSI) and mismatch repair deficiency are an emerging issue in oncology and molecular pathology. Besides being associated with better clinical outcome in colon cancer, MSI also harbors the potential to predict response to chemotherapy and immunotherapy. MSI was also observed in other solid tumors, including endometrial cancer, ovarian cancer, and melanoma, besides colon cancer. Strong evidence shows that MSI is a frequent event in melanoma. However, the data on MSI prevalence, pathogenesis, and clinical consequences in melanoma are limited...
September 12, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27623136/beneficial-in-vitro-effects-of-interleukin-2-interleukin-12-and-their-combination-on-functional-and-receptor-characteristics-of-natural-killer-cells-in-metastatic-melanoma-patients-with-normal-serum-lactate-dehydrogenase-levels
#13
Katarina M Mirjačić Martinović, Nada Lj Babović, Radan R Džodić, Vladimir B Jurišić, Aleksandra Z Ninković, Gordana M Konjević
Considering tumor-mediated suppression of natural killer (NK) cells, the aim of this study was to investigate the in-vitro effects of interleukin (IL)-2 and IL-12, as immunostimulatory cytokines, on the functional and receptor characteristics of NK cells and their subsets in healthy control (HC) and metastatic melanoma (MM) patients. Peripheral blood mononuclear cells of 27 HC and 35 MM patients were stimulated in vitro with IL-2, IL-12, and their combination for functional and phenotypic analysis. IL-2, IL-12, and primarily their combination, significantly induced NK cell activity, CD107a degranulation marker, and perforin expression in NK cells and their subsets in HC and MM patients...
September 10, 2016: Melanoma Research
https://www.readbyqxmd.com/read/27779554/thin-melanoma-subtyping-fits-well-with-the-american-joint-committee-on-cancer-staging-system
#14
Francesco Piscioli, Teresa Pusiol, Luca Roncati
No abstract text is available yet for this article.
December 2016: Melanoma Research
https://www.readbyqxmd.com/read/27779553/histopathological-determination-of-thin-melanomas-at-risk-for-metastasis
#15
Francesco Piscioli, Teresa Pusiol, Luca Roncati
No abstract text is available yet for this article.
December 2016: Melanoma Research
https://www.readbyqxmd.com/read/27584045/competing-risks-survival-of-older-patients-with-metastatic-cutaneous-melanoma-a-seer-population-based-study
#16
Jessica R Hoag, Upendra Hegde, Rebecca Zweifler, Marianne Berwick, Helen Swede
Mortality from metastatic cutaneous melanoma is substantially heterogeneous as reflected in three distant metastatic (M1) subtypes with metastasis to skin, subcutaneous tissue, or distant lymph nodes (M1a), conferring nearly half the risk of death compared with distant visceral metastasis (M1c). It remains unknown whether older patients experience the survival benefit from the M1a subtype given a higher overall mortality risk. Surveillance, Epidemiology, and End Result data were retrieved from 1878 metastatic melanoma patients, from 2005 to 2009, with follow-up through 2011...
October 2016: Melanoma Research
https://www.readbyqxmd.com/read/27482939/antiepidermis-autoantibodies-induced-by-anti-pd-1-therapy-in-metastatic-melanoma
#17
Florence Brunet-Possenti, Sabine Mignot, Lydia Deschamps, Vincent Descamps
Skin rashes induced by anti-PD-1s are often reported; however, their immunological profiles are currently unknown. We report the case of an atypical eruption induced by pembrolizumab, associated with the occurrence of antiepidermis autoantibodies. As the onset of lesions was concomitant with the favorable tumor response, we suggest that this hybrid rash belongs to a new category of paraneoplastic syndrome, reflecting the intense immunomodulation induced by pembrolizumab. With the increasing use of anti-PD-1s, this kind of report may become frequent...
October 2016: Melanoma Research
https://www.readbyqxmd.com/read/27467756/complete-response-to-high-dose-il-2-and-enhanced-ifn%C3%AE-th17%C3%A2-%C3%A2-treg-ratio-in-a-melanoma-patient
#18
Maggie L Diller, Ragini R Kudchadkar, Keith A Delman, David H Lawson, Mandy L Ford
High-dose IL-2 (HDIL-2) is associated with complete and durable responses in only 5-10% of patients with stage intravenous melanoma and the toxicity profile is significant. In-vivo human models have recently shown a stimulatory effect of exogenous IL-2 on both the Th17 and regulatory T-cell (TREG) compartments. We investigated and compared the effect of HDIL-2 on the Th17 and TREG compartments in HDIL-2 responders versus nonresponders. HDIL-2 was administered at a dose of 720 000 IU/kg to patients with melanoma (n=6) and peripheral blood was collected at baseline and at 24, 48, 72, and 96 h during treatment...
October 2016: Melanoma Research
https://www.readbyqxmd.com/read/27455380/galectin-9-modulates-immunity-by-promoting-th2-m2-differentiation-and-impacts-survival-in-patients-with-metastatic-melanoma
#19
Elizabeth Ann L Enninga, Wendy K Nevala, Shernan G Holtan, Alexey A Leontovich, Svetomir N Markovic
Galectin-9, a β-galactoside-binding protein, is defined as a negative regulator of T helper 1 (Th1) immune responses, favoring Th2 bias. Systemic immunity in patients with metastatic melanoma is predominantly Th2 biased. We hypothesized that galectin-9 can modulate systemic immunity toward Th2 polarization in patients with advanced melanoma. The presence or concentration of galectin-9 was assessed in tumors and plasma, in patients with metastatic melanoma. The immunomodulatory function of galectin-9 was determined by exposing human peripheral blood mononuclear cells to galectin-9 in vitro...
October 2016: Melanoma Research
https://www.readbyqxmd.com/read/27433783/braf-and-nras-mutations-in-russian-melanoma-patients-results-of-a-nationwide-study
#20
Georgiy A Frank, Svetlana N Aleksakhina, Larisa E Zavalishina, Tatiana V Kekeyeva, Aigul R Venina, Alexandr O Ivantsov, Natalia V Mitiushkina, Alla V Moiseyenko, Werner Pfeifer, Tatiana N Strelkova, Evgeny N Imyanitov
No abstract text is available yet for this article.
October 2016: Melanoma Research
journal
journal
30785
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"